Therapeutic potential of potassium channel modulators for CNS disorders

被引:6
作者
Clark, AG [1 ]
Booth, SE [1 ]
Morrow, JA [1 ]
机构
[1] Organon Res Labs Ltd, Newhouse ML1 5SH, Lanark, Scotland
关键词
BKCa channel; channelopathy; cognition; depression; epilepsy; K+ channel; K-ATP channel; KCNQ channel; Kv1.1; channel; neuroprotection; pain; SKCa channel; stroke;
D O I
10.1517/13543776.13.1.23
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Potassium (K+) channels play a pivotal role in the CNS, controlling cell excitability thereby raising their therapeutic application. In realisation of the utility of K+ channels, many pharmaceutical companies have developed a plethora of antagonists and openers for a range of disorders, including stroke, epilepsy, pain and cognition. The most promising targets, including BKCa, SKCa and KCNQ channels, will be reviewed in this article. The focus will be upon the most recent K+ channel modulator patents for CNS disorders and future developments of drugs for the treatment of CNS disorders.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 62 条
[1]  
BAYER AG, 2001, Patent No. 6174897
[2]   APAMIN, A SELECTIVE SK POTASSIUM CHANNEL BLOCKER, SUPPRESSES REM-SLEEP WITHOUT A COMPENSATORY REBOUND [J].
BENINGTON, JH ;
WOUDENBERG, MC ;
HELLER, HC .
BRAIN RESEARCH, 1995, 692 (1-2) :86-92
[3]   A potassium channel mutation in neonatal human epilepsy [J].
Biervert, C ;
Schroeder, BC ;
Kubisch, C ;
Berkovic, SF ;
Propping, P ;
Jentsch, TJ ;
Steinlein, OK .
SCIENCE, 1998, 279 (5349) :403-406
[4]  
*BMS, 2002, BMS204352
[5]  
BRISTOLMYERS SQUIBB, 1999, Patent No. 9938873
[6]  
BRISTOLMYERS SQUIBB, 2000, Patent No. 0034244
[7]  
BRISTOLMYERS SQUIBB, 1999, Patent No. 9938853
[8]  
BRISTOLMYERS SQUIBB, 1999, Patent No. 9938854
[9]  
BRISTOLMYERS SQUIBB, 1999, Patent No. 9938510
[10]  
Castlebury LA, 1999, WORLD J MICROB BIOT, V15, P131, DOI [10.1023/A:1008895421989, 10.1023/A:1008855406319]